| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 8,900 | 9,140 | 11:18 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.02. | Nexstim Oyj: Nexstim Plc's Financial Statements Bulletin 2025 | 409 | GlobeNewswire (Europe) | Company announcement, Helsinki 26 February 2026 at 9 am (EET)
NEXSTIM PLC'S FINANCIAL STATEMENTS BULLETIN 2025
NEXSTIM ACCELERATED GROWTH AND ACHIEVED A PROFITABLE RESULT
January-December 2025
The... ► Artikel lesen | |
| 19.02. | Nexstim Oyj: Nexstim's NBS 6 system receives MDR certification in the EU for use in Post-Operative Rehabilitation | 133 | GlobeNewswire (Europe) | Press release, Helsinki, 19 February 2026 at 9 AM (EET)
Nexstim's NBS 6 system receives MDR certification in the EU for use in Post-Operative Rehabilitation
Nexstim Plc ("Nexstim" or "Company") has... ► Artikel lesen | |
| 16.02. | Nexstim Oyj: Nexstim Receives Clearance for its NBS 6 Diagnostics System in UAE | 300 | GlobeNewswire (Europe) | Press release, Helsinki, 16 February 2026 at 11:30 AM (EET)
Nexstim Receives Clearance for its NBS 6 Diagnostics System in UAE
Nexstim Plc ("Nexstim" or "Company") has received import clearance for... ► Artikel lesen | |
| 02.02. | Nexstim Oyj: Nexstim Receives System Order from Distributor in India | 179 | GlobeNewswire (Europe) | Press release, Helsinki, 2 February 2026 at 9 AM (EET)
Nexstim Receives System Order from Distributor in India
Nexstim Plc ("Nexstim" or "Company") has received an order for an NBS System 5 through... ► Artikel lesen | |
| NEXSTIM Aktie jetzt für 0€ handeln | |||||
| 30.12.25 | Nexstim Receives U.S. Order For Two NBS 6 Therapy Systems | 5 | RTTNews | ||
| 30.12.25 | Nexstim Oyj: US Customer Orders Two Nexstim NBS 6 Therapy Systems | 341 | GlobeNewswire (Europe) | Press release, Helsinki, 30 December 2025 at 9 AM (EET)
US Customer Orders Two Nexstim NBS 6 Therapy Systems
Nexstim Plc ("Nexstim" or "Company") has received an order for two NBS 6 therapy systems... ► Artikel lesen | |
| 23.12.25 | Nexstim Oyj: Inside information: Nexstim Plc Agrees on Next Phase of Exclusivity Agreement with Sinaptica Therapeutics, Inc. | 155 | GlobeNewswire (Europe) | Company Announcement, Helsinki, 23 December 2025 at 9 AM (EET)
Inside information: Nexstim Plc Agrees on Next Phase of Exclusivity Agreement with Sinaptica Therapeutics, Inc.
Nexstim Plc ("Nexstim"... ► Artikel lesen | |
| 16.09.25 | Nexstim Oyj: Nexstim Receives NBS 5+ System Order from Therapy Customer in United States | 173 | GlobeNewswire (Europe) | Press release, Helsinki, 16 September 2025 at 9 AM (EEST)
Nexstim Receives NBS 5+ System Order from Therapy Customer in United States
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an... ► Artikel lesen | |
| 15.08.25 | Nexstim Oyj: Nexstim Plc Half-year Report January 1 - June 30, 2025 (unaudited) | 205 | GlobeNewswire (Europe) | NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 - JUNE 30, 2025 (UNAUDITED)
Company announcement, Helsinki, August 15, 2025 at 9 am (EEST)
NEXSTIM ACCELERATED GROWTH AND IMPROVED PROFITABILITY IN THE FIRST HALF... ► Artikel lesen | |
| 08.08.25 | Nexstim Oyj: Nexstim Receives NBS System 5 Order from India | 360 | GlobeNewswire (Europe) | Press release, Helsinki, 8 August 2025 at 10 AM (EEST)
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from an Indian distributor.
The end customer is a hospital... ► Artikel lesen | |
| 30.06.25 | Nexstim Oyj: Nexstim Plc Signs Exclusivity Agreement with Sinaptica Therapeutics, Inc. as Part of Planned Alzheimer's Collaboration | 148 | GlobeNewswire (Europe) | Company Announcement, Helsinki, 30 June 2025 at 9 AM (EEST)
Nexstim Plc Signs Exclusivity Agreement with Sinaptica Therapeutics, Inc. as Part of Planned Alzheimer's Collaboration
Nexstim Plc (NXTMH:HEX)... ► Artikel lesen | |
| 23.06.25 | Nexstim Oyj: Nexstim Receives NBS System 5 Order from a University Hospital in Germany | 243 | GlobeNewswire (Europe) | Press release, Helsinki, 23 June 2025 at 9 AM (EEST)
Nexstim Receives NBS System 5 Order from a University Hospital in Germany
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order... ► Artikel lesen | |
| 05.05.25 | Nexstim Oyj: Nexstim Plc Business Update Q1 2025 | 318 | GlobeNewswire (Europe) | Press release, Helsinki, 5 May 2025, at 9 AM (EEST)
Nexstim Plc Business Update Q1 2025
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces the key highlights of the Company's business operations... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| VERU | 2,540 | 0,00 % | Veru Inc.: Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress | -- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter- --Company to host conference call and webcast... ► Artikel lesen | |
| FRESENIUS | 46,950 | -2,55 % | DEUTSCHE BANK RESEARCH stuft Fresenius SE auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Fresenius mit einem Kursziel von 56 Euro auf "Buy" belassen. Analyst Falko Friedrichs lobte in seiner am Donnerstag vorliegenden... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 40,380 | -3,12 % | RBC stuft Siemens Healthineers auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat Siemens Healthineers mit einem Kursziel von 55 Euro auf "Outperform" belassen. Die Nervosität der Anleger vor einem möglichen Verkauf des Diagnostikgeschäfts... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 39,460 | +0,79 % | BARCLAYS stuft FMC FRESENIUS MEDICAL CARE AG auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für FMC von 47,50 auf 46,50 Euro gesenkt und die Einstufung auf "Equal Weight" belassen. Das Wachstum der Behandlungszahlen... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 18,860 | 0,00 % | Alignment Healthcare Reports Fourth Quarter and Full-Year 2025 Results; Beats High-End of Guidance Across All Key Metrics | Delivers full-year revenue of $3.95 billion, representing 46.1% growth year-over-year Exceeds high-end of fourth quarter and full-year guidance across all key metrics: membership, revenue, adjusted... ► Artikel lesen | |
| PROGYNY | 17,800 | 0,00 % | INVO Fertility, Inc.: INVO Fertility's Wisconsin Clinic Joins Progyny Network | ||
| PROCEPT BIOROBOTICS | 26,600 | +2,62 % | Truist cuts Procept BioRobotics stock price target on lower forecasts | ||
| GERRESHEIMER | 17,740 | +3,44 % | Gerresheimers Abschluss unter dem Röntgenblick der BaFin | Die BaFin verschärft den Blick auf die Rechnungslegung der Gerresheimer AG. Sie kündigt an, die am 18.09.2025 gestartete Anlassprüfung des offengelegten Konzernabschlusses und Konzernlageberichts 2023/2024... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 7,325 | 0,00 % | LifeStance Health Group, Inc. - 8-K, Current Report | ||
| CARL ZEISS MEDITEC | 25,580 | -1,16 % | INDEX-MONITOR: Lufthansa verpasst Dax-Rückkehr - Nur Wechsel in MDax und SDax | ZUG (dpa-AFX) - Die Aktien von Lufthansa haben die Rückkehr in den deutschen Leitindex Dax verpasst. Wie der zur Deutschen Börse gehörende Index-Anbieter Stoxx am späten Mittwochabend mitteilte, bleibt... ► Artikel lesen | |
| HEARTFLOW | 23,910 | 0,00 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| INNOVAGE | 10,610 | 0,00 % | InnovAge Announces Financial Results for the Fiscal Second Quarter Ended December 31, 2025 | DENVER, Feb. 03, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. ("InnovAge" or the "Company") (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly... ► Artikel lesen | |
| NEUROPACE | 13,960 | 0,00 % | Why NeuroPace Stock Was Inching Higher on Wednesday | ||
| ESSILORLUXOTTICA | 217,30 | -2,21 % | BARCLAYS stuft EssilorLuxottica auf 'Overweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für EssilorLuxottica mit einem Kursziel von 355 Euro auf "Overweight" belassen. Nutzzahlen zeigten, dass Smartglasses... ► Artikel lesen |